Medtronic Q4 Revenue Hits $9.8B; Plans Diabetes Unit Spin-Off, Boosts Dividend
MDT is trading near its 52-week low of $73.31 (6.7% above the low) on elevated volume (2.1× avg).
Summary
Medtronic reported strong Q4 results with $9.8 billion in revenue, up 9.9% year-over-year, and provided an optimistic FY27 organic revenue and EPS guidance. This follows the Q4 results reported yesterday, adding specific figures and forward-looking details. Crucially, the company announced plans to separate its diabetes unit through capital markets deals, potentially a spin-off, a significant strategic move to unlock value. Additionally, Medtronic saw U.S. market share gains in Cardiac Ablation Solutions and filed for expanded FDA indications for its Hugo robotic system, pointing to future growth. The company also raised its dividend, maintaining its Dividend Aristocrat status.
At the time of this announcement, MDT was trading at $78.21 on NYSE in the Life Sciences sector, with a market capitalization of approximately $100.1B. The 52-week trading range was $73.31 to $106.33. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Wiseek News.